Farallon Capital Management LLC Crinetics Pharmaceuticals, Inc. Transaction History
Farallon Capital Management LLC
- $17.4 Billion
- Q1 2025
A detailed history of Farallon Capital Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 4,605,098 shares of CRNX stock, worth $131 Million. This represents 0.89% of its overall portfolio holdings.
Number of Shares
4,605,098Holding current value
$131 Million% of portfolio
0.89%Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
228Shares Held
86.7MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.26MShares$264 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$196 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$178 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$177 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$146 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.53B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...